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Summary One hundred and fifty-seven patients with usual colorectal cancer were analysed prospectively for
DNA-ploidy, DNA-index and S-phase fraction (SPF) using flow cytometry. An abnormal DNA-stemline was
observed in 68% of tumours. The patients have been followed for a median of 36 months. In univariate
analysis, tumour stage was the most significant prognostic factor. After excluding patients with stage D
disease, DNA-aneuploidy was significantly associated with a shorter survival and a shorter disease free
survival. SPF, however, did not correlate with prognosis. In multiple samples from the same tumour there was
on average a 29% difference between the highest and the lowest SPF indicating considerable heterogeneity in
proliferative activity within the tumours. In diploid tumours the variation was even higher. Patients with
proximal tumours as well as female patients had DNA-diploid tumours more often than the others. This may
indicate that there are different, so far unknown, aetiological factors leading to different types of ploidy
pattern.
Traditionally, the classification and staging of colorectal car-
cinoma has been based on post-surgical histopathological
assessment of local tumour invasion depth and the presence
of lymph node or distant metastases (Dukes & Bussey, 1958).
Flow cytometric techniques can provide quantitative and
objective measurement of tumour DNA abnormalities and
proliferative activity (Shapiro, 1989). This information has
proved useful for supplementing clinical and pathological
classification of many malignant diseases (Seckinger et al.,
1989). An accumulating body of data supports the view that
flow cytometric detection of an abnormal DNA content in
cells and the degree of DNA abnormality and/or proliferative
activity in most malignancies may reflect the degree of malig-
nancy and clinical behaviour (Seckinger et al., 1989). In
reports on DNA-abnormalities in colorectal carcinomas,
aneuploidy correlates with lower survival rates than diploidy
(Wolley et al., 1982; Armitage et al., 1985; Kokal et al., 1986;
Goh et al., 1987; Scott et al., 1987a,b; Quirke et al., 1987;
Jones et al., 1988), although the results are somewhat contro-
versial (Melamed et al., 1986; Schutte et al., 1987; Wiggers et
al., 1988). Also, a high S-phase fraction (SPF) has shown an
association with poorer survival (Bauer et al., 1987).
In this study we have analysed prospectively 157 fresh
primary colorectal carcinomas obtained at the Second
Department of Surgery, Helsinki University Central Hospital
and examined the prognostic value of flow cytometry derived
DNA data such as DNA-ploidy, DNA index and SPF. This
is the largest prospective study to date uding fresh samples of
colorectal carcinomas. Also, for the first time, patients with
the cancer family syndrome have been segregated from usual
carcinoma patients because of their different type of DNA
ploidy pattern (Kouri et al., 1990).
Materials and methods
Patients
One hundred and fifty-seven patients operated on at the
Second Department of Surgery of Helsinki University Cen-
tral Hospital, between November 1983 and April 1988 were
included in this study. Patients with a previous history of
cancer, cancer family syndrome, ulcerative colitis or familial
colorectal polyposis were excluded from this series. Data
were collected from patient's records on age, sex, tumour
stage, and site and size of the tumour. In six cases the size of
the tumour was not measured. The ACPS classification of
tumour stage was used (Davis & Newland, 1983). The
tumours were classified as right-sided (e.g. those proximal to
splenic flexure) left-sided and rectal.
Follow-up
Follow-up visits took place once every 6 months during the
first 2 years, and then yearly thereafter up to 5 years.
Routinely the visits included a physical examination, sig-
moidoscopy and blood tests including serum carcinoembry-
onic antigen. Recurrence was dated from the first evidence of
relapse, based on physical, histological or imaging data. The
time of death and cause of death was recovered from hospital
records and from the Central Statistical Office of Finland.
The patients have been followed for a median of 36 months
(range 13-67 months). Thirty-six of the 125 patients with
stage A-C disease developed a locoregional and/or distant
recurrence during the follow-up. Twenty-two of them died
before the closing date. Twenty-six of 32 patients with stage
D disease died before the closing date. In addition, 14
patients died without reported recurrence and were treated as
censored observations in the analysis.
Flow cytometric analysis
Biopsies from each tumour for flow cytometric DNA-analysis
were immediately frozen in liquid nitrogen and stored
thereafter at - 80°C until analysis. At the time of analysis,
the tumour samples were rapidly thawed in a 37°C water
bath and processed immediately into single-cell suspensions
by scalpel and scissors. The suspension was filtered through a
50 tm nylon mesh. The filtrate was centrifuged for 7 min at
1,600 r.p.m. Chicken and trout red blood cells were added as
internal standards in most of the samples (Vindel0v et al.,
1983).
The pellet was resuspended in 0.5 ml of ethidium bromide
(50 tg ml ' in 1OmM Tris buffer, 1 mM EDTA, 0.3% Noni-
dent P40, pH 7.5). The tube was vortexed and held on ice for
15 min. Then 0.25 ml of solution containing 1 mg ml-'
RNAse (Sigma) was added to the tube and incubated for
15 min at room temperature. Immediately before analysis the
sample was filtered through the nylon mesh.
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Routinely, 70,000 or 15,000 cells per sample were analysed
on a FACS IV Cell-Sorter (Becton Dickinson) or an EPICS
C flow cytometer (Coulter), respectively. The first 69 tumours
were analysed by the FACS and the subsequent 88 by the
EPICS flow cytometer. In a study on flow cytometry of
thyroid tumours 25 samples were analysed on both the
FACS and the EPICS flow cytometer. There were no differ-
ences in the results (unpublished). With the EPICS a 2 W
Argon-ion laser was used for excitation at 488 nm, 200 mW,
and the total emission above 590 nm was measured. The
mean coefficient of variation of the diploid peak was 4.9%.
The flow- cytometric parameters evaluated included the
DNA-ploidy and DNA-Index (DI, where DI represented the
ratio of the aneuploid stem line GI/Go-DNA peak channel to
the diploid stem line G1/Go-DNA peak channel). Tumours
were classified as diploid and aneuploid, and aneuploid
tumours with a DI between 1.9 and 2.1 and a definable S-
and G2/M-phase as tetraploid. The tumours were classified as
aneuploid only if there were at least two GI/Go peaks. In
tumours with multiploid aneuploid peaks the DNA-index of
the aneuploid peak with the highest peak ratio was used. The
SPF was calculated based on a rectangular model as de-
scribed by Baich et al. (1975). The mean S-phase channel
count was calculated from the shoulder of the GI/S phase to
the shoulder of the S/G2 phase. The proliferative index (PI) is
the sum of the percentage of cells in G2/M-phase and SPF.
When multiple samples were analysed, the mean values of
SPF and PI were used. SPF analysis was not possible in 35
cases. The criteria for exclusion from cell cycle analysis were
overlapping histograms (n = 29), high background debris
(n = 4) and high CV (n = 2). The peak ratio of aneuploid
tumours was calculated by dividing the counts of the aneu-
ploid GI/Go peak by the counts of the diploid GI/Go peak.
Statistical description and analysis
Differences between mean values were analysed using a
Student's t test, and differences between frequencies with
contingency tables.
For calculation of disease-free survival and overall sur-
vival, product limit survival analysis was performed using the
BMDP 1L computer program (Dixon, 1988). Calculations of
the significance of observed differences were performed using
the log rank test (Mantel-Cox). Patients with stage D
disease were included in this material for the calculation of
overall survival rates, but this category of patients was ex-
cluded for the calculation of the disease-free-interval.
The relative prognostic importance of all parameters was
investigated using Cox's regression model and the BMDP 2L
computer program (Dixon, 1988). A prognostic variable with
two or more categories of outcome is represented by a
number of variables and parameters equal to the number of
its categories minus one. The reference category was not
included as a variable.
Results
Overall 106 of 157 (68%) tumours showed an abnormal
DNA stemline (Figure 1). Eighty-eight of 157 tumours (56%)
were classified as aneuploid, 18 of 157 (12%) as tetraploid
and 51 of 157 (32%) as diploid. The DNA-index values
ranged from 1.00 to 3.21. Multiple samples were analysed in
81 carcinomas. Sixty-five (80%) of them were homogeneous,
and 10 (12%) heterogenous with respect to DNA-ploidy. In
addition, six (8%) tumours had detectable biclonal aneuploid
stemlines.
DNA-cytokinetic analysis was possible in 122 cases. The
SPF for these colorectal cancers ranged from 8.5 to 46.6%.
The median SPF was estimated to be 22.3%. DNA-aneu-
ploid tumours had a significantly higher SPF as compared
with DNA-diploid tumours (27.1%, 17.5%, respectively,
P = 0.001). In 44 tumours multiple samples were analysed
for SPF. In these tumours, there was an average difference of
29% between the highest and the lowest SPF. The variation
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Figure I The DNA histograms of diploid a, aneuploid b, and
tetraploid c, tumours. Chicken (first peak) and trout (second
peak) blood cells were added as internal control in the samples.
in SPF increased significantly with increasing number of
samples, especially in diploid tumours (P = 0.019). In diploid
tumours with two samples the average difference was 27%
(n = 16), but as high as 64% with three or more samples
(n = 4). In aneuploid with two samples the average difference
was 24% (n = 17), and with three or more samples 28%
(n = 7).
Aneuploid tumours were more frequent in male than
female patients (Table I). The frequency of aneuploidy in-
creased with increasing level of direct spread of the primary
tumour. However, the presence of lymph node or distant
metastasis did not differ by ploidy. Seventy-four per cent of
rectal and 63% of colonic tumours were aneuploid. The
distribution of DNA-indices however, did not differ by
tumour site (Figure 2).
In univariate analysis of the importance prognostic variables
tumour stage was the most important prognostic parameter
(Table II). When the depth ofdirect spread, presence oflymph
nodal or distant metastasis were analysed separately, each one
was associated with survival. Patients with aneuploid tumours
had a worse prognosis than those with diploid or tetraploid
tumours (Table III), although not statistically significantly.
When diploid and tetraploid tumours were grouped together,
there was a borderline significant difference in survival as
compared with aneuploid tumours (X2 = 3.51, P = 0.061, log
rank test). In patients with stage D disease the survival did
not correlate with ploidy (Figure 3d). After excluding these
patients the difference in survival between aneuploid and
diploid tumours was statistically significant both when tetrap-
loid tumours were grouped into aneuploid or diploid
tumours. SPF, PI or peak ratio ofaneuploid tumours did not
correlate with survival.
Since 14 of the 36 patients with relapsed disease were still
alive at the time of analysis, a disease-free survival analysis of
patients with stage A-C disease was performed separately
(Tables IV and V, Figure 3a-c). Patients with aneuploid
tumours had a significantly shorter disease-free survival than978 M. KOURI et al.
Table I Patient and tumour characteristics related to DNA-ploidy
in 157 cases of colorectal carcinoma
Per cent
Variable n aneuploid
Sex
Male 83 76
Female 74 58*
Age (years)
<60 48 69
60-70 40 75
>70 69 62
Location
Right colon 39 56
Left colon 49 67
Rectum 69 74
Stage
A 27 63
B 64 67
C 34 71
D 32 69
Depth of invasion
Submucoas 4 50
Muscularis propria 27 63
Beyond muscularis propria 10 60
Mesothgelial surface 99 70
Adjacent tissue or organ 17 71
Lymph node metastasis
Absent 101 66
Present 56 70
Distant metastasis
Absent 130 67
Present 27 70
*P = 0.018.
Table II Relationship ofclinicopathological variables to survival of
157 patients with colorectal cancer using product limit survival
analysis and the log rank test
Observedl
Variable n expected x2 p
Sex
Male 83 1.21
Female 74 0.81 1.90 >0.05
Age (years)
<60 48 0.88
60-70 40 0.93
>70 69 1.14 0.69 >0.05
Location
Right colon 39 1.00
Left colon 49 1.11
Rectum 69 0.93 0.29 >0.05
Stage
A 27 0.31
B 64 0.41
C 34 0.95
D 32 4.43 82.56 <0.001
Depth of invasion
Submucosa 4 0.63
Muscularis propria 27 0.32
Beyond muscularis propria 10 0.30
Mesothelial surface 99 1.21
Adjacent tissue or organ 17 1.65 9.60 0.048
Lymph node metastasis
Absent 101 0.49
Present 56 2.30 32.11 <0.001
Distant metastasis
Absent 130 0.52
Present 27 6.39 127.03 <0.001
Tumour size (cm)
<3.5 52 0.79
3.6-5.0 52 1.07
>5.0 47 1.16 1.04 >0.05
1.0 1.2 1.4 1.6 1.8 2.0 2.2 3.0 3.2
DNA-index
Figure 2 The distribution of DNA-indices by site of tumour.
Symbols used in the graph: 0 right colon; 12 left colon; -
rectum.
those with diploid tumours (X2 = 4.77, P = 0.029, log rank
test). This difference was even more significant when diploid
and tetraploid tumours were combined (X2 = 7.23, P = 0.007,
log rank test).
When the prognostic value of different clinicopathological
variables on disease-free survival was estimated in multi-
variate analysis, only stage and ploidy correlated with sur-
vival. Stage was the most significant prognostic parameter.
Aneuploid tumours had a poorer prognosis than diploid
tumours. Tetraploid tumours had a hazard ratio similar to
that for diploid tumours. SPF, PI or peak ratio entered as
continuous or categorial variables did not correlate with
survival.
Discussion
We have analysed the prognostic value of DNA-ploidy,
DNA-index and S-phase fraction prospectively in 157 colo-
rectal carcinomas. In univariate analysis patients with stage
Table III Relationship of DNA-ploidy, DNA-index, SPF, PI and
peak ratio to survival of 157 patients with colorectal cancer using
product limit survival analysis and the log rank test
Observedl
Variable n expected x2 p
Ploidy
Diploid 51 0.71
Aneuploid 106 1.16 2.24 >0.05
Ploidy
Diploid 51 0.71
Aneuploid 88 1.25
Tetraploid 18 0.72 3.51 >0.05
Ploidy
Diploid and tetraploid 69 0.71
Aneuploid 88 1.25 3.51 >0.05
DNA-index
1.0 51 0.71
1.1 -1.4 33 1.68
1.5- 1.8 50 1.04
1.9-2.1 18 0.72
2.2 + 5 0.62 6.59 >0.05
SPF
K22% 61 0.91
>22% 61 1.10 0.32 >0.05
PI
<28% 62 0.83
>28% 60 1.20 1.17 >0.05
Peak ratio
< 1.0 49 0.85
> 1.0 50 1.17 0.80 >0.05
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Table IV Relationship of clinicopathological variables to
disease-free survival of 125 patients with colorectal cancer of tumour
stage A-C using product limit survival analysis and the log rank
test
Observedl
Variable n expected x2 p
Sex
Male 65 1.00
Female 60 1.00 0.00 >0.05
Age (years)
<60 39 1.02
60-70 32 0.93
> 70 54 1.03 0.07 >0.05
Location
Right colon 29 0.70
Left colon 35 0.75
Rectum 61 1.31 3.04 >0.05
Stage
A 27 0.32
B 64 0.68
C 34 2.62 27.02 <0.001
Tumour size (cm)
<3.5 47 0.92
3.6-5.0 46 1.33
> 5.0 31 0.70 2.28 >0.05
48 60
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Figure 3 a-c, The disease free survival curves for patients with
tumour stage A-C. The number of patients at risk is shown
below the figures. For patients with tumour stage A-C there is a
statistically significant difference in disease-free survival between
aneuploid, tetraploid and diploid tumours either as a group
(x2 = 7.27, P = 0.026, log rank test) or stratified by stage
(X2 = 8.69, P = 0.013, log rank test). d, The survival of patients
with stage D disease did not differ by ploidy. Symbols used in the
figure: diploid tumour; aneuploid tumour;
tetraploid tumour.
A-C aneuploid tumours had a significantly poorer overall
survival as well as disease-free survival than those with
diploid and tetraploid tumours. This difference remained
significant when tumour stage was included in a multivariate
analysis.
In the present study only patients with usual colorectal
carcinoma and without a history of previous malignancy
were included. Recently we have shown that patients with
cancer family syndrome have mainly DNA-diploid colorectal
carcinomas (Kouri et al., 1990). Of all colorectal carcinoma
Table V Relationship of DNA-ploidy, DNA-index, SPF, PI and
peak ratio to disease-free survival of 125 patients with colorectal
cancer of tumour stage A-C using product limit survival analysis
and the log rank test
Observed!
Variable n expected x2 p
Ploidy
Diploid 41 0.53
Aneuploid 84 1.28 4.77 0.029
Ploidy
Diploid 41 0.53
Aneuploid 69 1.45
Tetraploid 15 0.63 7.27 0.026
Ploidy
Diploid and tetraploid 56 0.55
Aneuploid 69 1.45 7.23 0.007
DNA-index
1.0 41 0.53
1.1-1.4 23 1.40
1.5- 1.8 41 1.34
1.9-2.1 15 0.63
2.2 + 5 2.71 9.22 >0.05
SPF
<22% 50 0.96
>22% 48 1.05 0.05 >0.05
PI
-<,28% 51 0.94
>28% 47 1.08 0.15 >0.05
Peak ratio
<' 1.0 41 0.84
> 1.0 38 1.21 0.92 >0.05
patients 5-6% have a cancer family syndrome (Mecklin,
1987) and these patients seem to have a favourable prog-
nosis. Based on these findings CFS patients should be treated
separately when analysing DNA ploidy of colorectal cancer.
Previously, it has been reported that proximal tumours are
more often diploid than distal ones (Rognum et al., 1987,
Scott et al., 1987b, Jones et al., 1988). Our results support
these findings. Even when the patients with known CFS were
excluded from this series, only 56% of right-sided tumours
were aneuploid in contrast to 67% of left-sided and 74% of
rectal tumours. The difference was not, however, statistically
significant. Similar to the findings of Rognum et al. (1987)
aneuploidy was more frequent in male than female patients.
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These findings suggest that there may be two or more genetic
types of colorectal cancer leading to different types of ploidy
pattern. These types could correspond to the two inherited
colorectal cancer syndromes: familial adenomatosis and CFS
as suggested by Knudson (1989).
DNA-ploidy had no prognostic value in patients with
locally advanced or metastatic (stage D) disease as has been
reported previously (Schutte et al., 1987; Rognum et al.,
1987). When the analysis was limited to patients with stage
A-C disease, a significant difference in disease-free survival
and also in overall survival was observed. In most of the
published studies the survival rate of patients with diploid
tumours has been 14-27% better than the survival of
patients with aneuploid tumours. When compared by stage,
the survival difference has usually been observed in patients
with lymph nodal metastastasis. This is predictable since the
overall number of events, e.g. deaths or relapses, due to
cancer is high in stage C tumours. In contrast, more than
90% of patients with stage A disease can be cured.
The limit of defining an aneuploid peak has been shown to
affect the results concerning DNA ploidy and survival (Jones
et al., 1988). Classification of DNA-histograms of small
aneuploid peaks is especially difficult in samples with a high
coefficient of variation, usual in series using paraffin
blocks for DNA analysis. The calculation of DNA-index
may also be difficult in some cases due to the lack of an
internal control. In fresh samples using chicken or trout
blood cells as internal controls these problems can be
alleviated (Vindel0v et al., 1983). Previously in two studies
(Scott et al., 1987a; Jones et al., 1988) it was found that
tumours with large aneuploid peaks had a worse prognosis
than those with smaller aneuploid peaks. Both these studies
used paraffin embedded archival material for DNA analysis.
In our study using fresh samples we could not reproduce
these observations. Most probably, a variation between sam-
ples from the same tumour would limit the usefulness of
peak ratio as a prognostic factor.
Tetraploid tumours had a better prognosis than other
aneuploid tumours. Grouping tetraploid and diploid tumours
together increased the prognostic value of DNA ploidy. This
is in agreement with the findings of Quirke et al. (1987) but
disagrees with those of Jones et al. (1988) and Scott et al.
(1987a). In previous studies the frequency of tetraploid
tumours has varied from 4% (Kokal et al., 1986) to 24%
(Jones et al., 1988) which reflects the difficulties in defining
tetraploidy. It would be reasonable to suppose that tumours
classified as tetraploid based on DNA-index have a
heterogeneous pattern of DNA abnormalities. This would
explain the discrepancies found in the literature.
SPF or PI did not have a prognostic value in colorectal
carcinomas unlike in breast and ovarian carcinomas (Kal-
lioniemi et al., 1988a,b). This finding did not change when
diploid and aneuploid tumours were analysed separately or
when SPF was entered as a continuous variable or grouped
in two or three categories. In aneuploid tumours even taking
the peak ratio into account the SPF was not associated with
survival. In most studies on colorectal carcinoma published
so far, the cell cycle has not been analysed, probably because
of technical difficulties in determining the SPF. In three
studies, the prognostic value of SPF or PI has been reported.
Bauer et al. (1987), using paraffin samples, report SPF values
in 99% of the analysed samples and showed that SPF is an
even more significant prognostic factor than DNA ploidy.
Schutte et al. (1987) were able to calculate SPF in 70% of the
samples and reported an association between SPF and sur-
vival, similar to that of the ploidy level. Quirke et al. (1987)
analysed PI only in diploid tumours and diploid areas of
aneuploid tumours and found an association between a high
PI and a poor survival.
The heterogeneity of colorectal carcinomas seems to be the
most important reason for the large variance of SPF. In the
present study an average difference of 29% in SPF between
samples from the same tumour was observed. The difference
was even more pronounced in diploid tumours. The basic
problem in cell cycle analysis is the separation between
malignant and non-malignant cells. In diploid samples, the
percent of malignant cells can vary in different samples mak-
ing the estimates of SPF less precise. In aneuploid samples
with near-diploid peaks, SPF calculation is less accurate due
to overlapping cell cycle histograms. Also background debris,
especially in paraffin samples, may disturb cell cycle analysis.
To eliminate this problem Bauer et al. (1987) electronically
subtracted the debris area with suitable software. It seems
obvious that for SPF determination to be more accurate in
fresh samples, multiple samples should be used. Better
methods for separation of malignant cell population are also
needed.
In the current prospective study using fresh samples of
usual colorectal carcinomas, the results show that DNA-
aneuploidy is associated with poorer prognosis in patients
with stage A-C disease. Tumour stage is, however, the most
important prognostic factor. The clinical value of SPF needs
to be studied further, especially in methodological aspects.
Flow cytometric DNA-analysis may be useful in classifying
different subgroups of colorectal carcinomas with different
clinicopathological features as shown with cancer family syn-
drome. This may lead to a better understanding of tumour
progression and even to selection of surgically treated
patients into new adjuvant treatment protocols.
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